Metagenomi (NASDAQ:MGX) Price Target Raised to $14.00

Metagenomi (NASDAQ:MGX) had its target price boosted by HC Wainwright from $7.00 to $14.00 in a report released on Tuesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other research firms have also recently issued reports on MGX. Chardan Capital reaffirmed a “buy” rating and set a $15.00 price objective on shares of Metagenomi in a research report on Wednesday, November 20th. BMO Capital Markets decreased their price objective on shares of Metagenomi from $22.00 to $17.00 and set an “outperform” rating for the company in a research report on Thursday, August 15th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.67.

Metagenomi Stock Down 2.3 %

NASDAQ:MGX opened at $3.86 on Tuesday. The company has a 50 day moving average price of $2.14 and a 200 day moving average price of $3.30. Metagenomi has a fifty-two week low of $1.61 and a fifty-two week high of $12.74.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Rhumbline Advisers bought a new position in Metagenomi during the 2nd quarter valued at $26,000. BNP Paribas Financial Markets boosted its stake in Metagenomi by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock valued at $28,000 after acquiring an additional 7,256 shares during the last quarter. Virtu Financial LLC bought a new position in Metagenomi during the 3rd quarter valued at $33,000. XTX Topco Ltd bought a new position in Metagenomi during the 2nd quarter valued at $66,000. Finally, Green Alpha Advisors LLC bought a new position in Metagenomi during the 3rd quarter valued at $69,000.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.